
Photo by Innerbody Research
A passing gut issue can ruin your day. Besides the time spent in the bathroom, there’s all the bloating and gas that can kill your physical discomfort and push your self-consciousness into overdrive. And imagine if the gut problem weren’t a passing thing but rather of indefinite duration, like with SIBO. It’s enough to make a person desperate for a solution in the supplements aisle, where more than a few probiotics offer the potential for relief.
As is the case with all supplements, some SIBO probiotics are better than others. The best ones are no guaranteed remedy, and you’ll want to consult a medical provider as to their suitability for your recovery, but the quality they have in common is they contain specific probiotic microorganisms that have acquitted themselves relatively well in clinical research.
See our summary of recommendations just below for the rundown. Then read further to see how we made our selections.
Florastor Dual Action Probiotic contains Saccharomyces boulardii CNCM I-745, the most researched probiotic strain in direct SIBO studies.
In addition, Florastor’s CNCM I-745 has been the subject of successful research related to gut health, and while the CFU isn’t specified on the label, other documentation suggests that it contains a clinically relevant 10 billion CFU of the S. boulardii yeast probiotic. It’s pricier than our other recommendations, but the current scientific literature finds that it offers the best potential to help eliminate SIBO and restore the gut microbiome as an adjunct therapy. This product is available on both Amazon and iHerb, but we suggest iHerb since it allows for the greatest flexibility in order quantity, including a smaller and less expensive 20-capsule order.
Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.
This guide to the best SIBO probiotics synthesizes both the theoretical and the practical knowledge that we gained over nearly 100 hours of research effort. We first searched and studied the literature on SIBO and the role that probiotics may play in treating it. We then applied this knowledge to identifying probiotic supplements whose formulations aligned with direct or tangential clinical studies. With a shortlist in place, we finally ordered the market’s best SIBO probiotics ourselves so that we could speak to the customer experience.
Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.
We selected the products in this guide based on three criteria that are the likeliest to move consumer decisions:
Here’s how our top recommendations rated in each category.
Advantage: Florastor Dual Action Probiotic
In the current body of research on SIBO probiotics, one strain stands out for having withstood the most scrutiny, so far, in direct SIBO studies: Saccharomyces boulardii CNCM I-745. This is the strain that led to an 80% SIBO elimination rate in one randomized clinical trial and decreased hydrogen excretion better than placebo in a separate study.15 21 It’s also the strain that runs solo in Florastor Dual Action Probiotic, in what appears to be a clinically relevant dose,23 24 and the brand itself has been tested in at least one successful trial of a product containing the strain.22 When all such factors are considered, Florastor rises above the competition.
Another of our recommendations, NOW Foods, uses S. boulardii as well, but it doesn’t identify the strain. The species in general is well-studied for gut health improvements, but the lack of a strain designation means we can’t be more specific than that. It’s rather an entry-level product for people who prioritize an ultra-low price tag.
Our other two recs, Microbiome Labs and BioGaia, are excellent in their own rights, but they either lack direct SIBO testing or are better suited for a narrower cohort of SIBO patients. We discuss their strengths in their respective brand sections near the end of this guide.
Advantage: BioGaia Gastrus Probiotic Chewables
While S. boulardii has the most research support behind it, it’s also a theoretically risky option since it has been linked to a life-threatening infection called Saccharomyces fungemia.19 Although the risk principally relates to people with immunocompromise, critical illness, or indwelling catheters, it’s a serious factor that brings down the species’ value in terms of safety.
But Limosilactobacillus reuteri poses no such risk. In fact, it boasts a fair bit of human safety data. A 2024 randomized clinical trial, which administered L. reuteri DSM 17938 and ATCC PTA 6475, found that the frequency of adverse events was similar between the intervention and placebo groups,35 suggesting that the two strains hardly differed from baseline in terms of their safety profiles. The same two strains are those used in BioGaia Gastrus Probiotic Chewables.
We want to make clear that, for the overwhelming majority of potential users, the infection risk associated with S. boulardii is very small. Yet when you compare the risk with L. reuteri, it’s the latter species that presents as the more reassuring therapeutic option. And when you compare BioGaia’s L. reuteri strains with the three Bacillus ones in Microbiome Labs, you find that only BioGaia’s exact combination has been evaluated for safety. BioGaia, therefore, stands out as the safest recommendation in our guide.
Advantage: Microbiome Labs RestorFlora
Microbiome Labs isn’t the lowest-cost option in our guide, or even the most cost-effective, but with its combination of a complex formulation and relatively large quantity, it offers the most might for your money. This table illustrates:
| Strain-specific probiotics | Price tag | Servings per bottle | Per-serving cost | |
|---|---|---|---|---|
| Microbiome Labs | 4 | $41.19 – $45.77 | 60 | $0.69 – $0.76 |
| NOW Foods | 0 (1 nonspecific) | $21.99 – $39.99 | 30 – 60 | $0.67 – $0.73 |
| BioGaia | 2 | $24.64 – $42.00 | 30 – 60 | $0.70 – $0.97 |
| Florastor | 1 | $19.82 – $67.99 | 10 – 50 | $1.36 – $1.98 |
At its subscription level, Microbiome Labs costs only $0.02 more per serving than NOW Foods while providing four strain-specific probiotics as opposed to NOW Foods’ one nonspecific S. boulardii species. Moreover, Microbiome’s per-serving cost range is lower than that of BioGaia or Florastor, which also have fewer strains in their formulations.
That being said, if the up-front cost is your primary constraint, then NOW Foods is the obvious choice. Even its higher-quantity offering costs less than its Microbiome Labs and BioGaia counterparts, while Florastor simply costs too much more per serving to compete seriously in this category
Before we get into the science behind SIBO and SIBO probiotics, check out this quick-reference table comparing our recommendations in key categories:
| Florastor | Microbiome Labs | BioGaia | NOW Foods | |
|---|---|---|---|---|
| Species/strains | S. boulardii CNCM I-745 | S. boulardii CNCM I-1079, B. subtilis HU58, B. coagulans SC208, B. clausii SC109 | L. reuteri DSM 17938, L. reuteri ATCC PTA 6475 | S. boulardii (strain unspecified) |
| One-time $ | $19.82 – $67.99 | $45.77 | $28.99 – $42.00 | $21.99 – $39.99 |
| Subscription $ | N/A | $41.19 | $24.64 | N/A |
| Free shipping? | On orders of $24.99 and up | For Prime members | On subscriptions | No |
| Refunds on direct purchases | 30 days, potentially allows opened items | 45 days, with authorization | 30 days, with authorization | 30 days, unopened items only |
Small intestinal bacterial overgrowth (SIBO) is a bowel disorder in which the small intestine plays host to an abnormal quantity or combination of bacteria.
Ordinarily it’s the colon that houses the most microorganisms, partly because food residues move through it more slowly, giving bacteria more time to multiply. And that’s fine, because with its dual-layer mucus barrier, the colon is adapted to accommodate large bacterial loads.1 With the small intestine, that isn’t the case; it’s supposed to assume a different role involving digestion and nutrient absorption, processes that can be disrupted by excessive bacterial growth or an abnormal bacterial composition.2
Indeed, SIBO can throw a wrench into your digestive processes. During normal digestion, the small intestine absorbs most nutrients before food reaches the colon, and the colon is where microbes ferment the carbohydrates and fibers the body did not digest.2 But in SIBO, the food is besieged by fermenting bacteria much earlier, potentially impairing nutrient absorption and producing gases that stretch the intestine, contributing to symptoms such as:3
Some bacteria may even alter the bile salts necessary to digest fat, allowing unabsorbed/undigested fat to pass into the colon and come out as greasy stool.4 3 In more serious cases, the impairment to nutrient absorption may lead to vitamin deficiencies — not only of the fat-soluble variety but also of vitamin B12 — and the bacterial overgrowth damages gut lining, which may in turn lead to health issues downstream, such as osteoporosis and/or kidney stones from attendant calcium malabsorption.5
You’ll notice these symptoms are common to other gastrointestinal conditions, so a proper diagnosis should require something like breath testing and/or stool testing.
SIBO may arise when one or more of the following gastrointestinal characteristics weaken:6
Higher intragastic pH equals lower gastric acidity, which correlates with an increase in gastrointestinal microorganisms.7 Several factors may lead or contribute to reduced gastric acidity, including gastric bypass surgery, Helicobacter pylori infection, and prolonged use of certain medications, such as antacids and proton pump inhibitors.
A healthy gut microbiome is a balanced community of beneficial microorganisms, but it can be thrown off-kilter. Besides proton pump inhibitors, antibiotics and narcotics are known to disrupt the balance.
Gut motility refers to the movement of food through the gastrointestinal tract. When normal motility slows, waste remains too long in the small intestine, allowing bacteria to multiply. The potential causes here are numerous but can generally be categorized as either a myopathy (abnormality of the musculature) or a neuropathy (damage or disease affecting the nerves).8
In addition to myopathies, certain structural issues can affect normal motility and allow bacteria to colonize the small intestine. These include internal abdominal scarring, intestinal blockages, and small bowel diverticulosis.
Multiple secondary factors increase one’s susceptibility to these causative factors. Age, for example, correlates with slower gut motility and lower gastric acid levels; abdominal surgery and radiation exposure elevate the risk of structural damage; and many health conditions can affect both motility and intestinal structure:6
SIBO is categorized according to the main gases produced by the bacterial overgrowth in the small intestine, as measured by a breath test:
In hydrogen-dominant SIBO, bacteria in the small intestine produce high levels of hydrogen. It’s diagnostically characterized by a hydrogen gas rise greater than 20ppm from baseline within 90 minutes.36
Colloquially known as methane SIBO, IMO results from small intestinal colonization by single-celled organisms called archaea, which produce methane. In addition to some of the more common SIBO symptoms, IMO may be symptomized by constipation.37
Hydrogen sulfide–predominant overgrowth involves bacteria that consume hydrogen and sulfur-containing compounds to produce hydrogen sulfide. Some labs regard a hydrogen sulfide level greater than 3ppm to be diagnostic of this variant.
What may initially seem counterintuitive — adding microorganisms in a disorder characterized by bacterial overcolonization — might make sense if you change your perspective.
Imagine your small intestine as a home garden, and SIBO as an infestation of aphids. While you could bombard the whole thing with something like a pesticide, which might harm your crops as much as the pests, there’s also a nondestructive method at your disposal: adding ladybugs to the ecosystem. Because a single ladybug can eat up to 5,000 aphids in its lifetime,9 a few dozen or a couple hundred of the spotted lovelies could reasonably control your pest problem and allow your plants to thrive.
With SIBO, it’s roughly the same situation. Similar to how ladybugs compete with aphids, helpful microorganisms in a probiotic supplement can compete with the bad actors in your small intestine and eventually edge them out for nutrients and attachment sites. Potentially, the probiotics may also confer benefits related to bowel function and motility that counter some of SIBO’s ill effects.
The probiotic-only treatment method finds some, albeit low-quality, support in clinical research. For example:
Since clinical research on the matter is limited, there’s nothing resembling a standard probiotic regimen for treating SIBO. The American Gastroenterological Association doesn’t even mention probiotics in its 2020 best-practice recommendations, instead advising that “management should focus on the identification and correction ... of underlying causes, correction of nutritional deficiencies, and the administration of antibiotics.”12
For most people, then, the place that probiotics hold in their SIBO treatment protocol may be as an adjunct rather than a stand-alone therapy. Especially if antibiotics are part of the treatment, a probiotic supplement may help reduce the risk of developing common antibiotic side effects, such as diarrhea, and perhaps more quickly restore one’s gut microbiome.13
That being said, the efficacy of any therapeutic option may depend on the individual. In some cases, probiotics alone may make a meaningful difference.
Specific probiotic species share certain characteristics that make them more suitable than others for SIBO, and more narrowly, specific strains may be capable of conferring benefits that are particularly helpful for mitigating SIBO’s symptoms.
Below are some species and/or strains that have acquitted themselves fairly well in SIBO-related studies.
Saccharomyces boulardii is a species of probiotic yeast, not bacteria. As such, it’s resistant to antibiotics and is therefore an attractive option to take alongside antibiotic therapy.
Plus, it has yielded some promising results in clinical research. One open pilot trial, which compared S. boulardii, the antibiotic metronidazole, and their combination, documented SIBO eradication rates of 33%, 25%, and 55%, respectively, with S. boulardii groups reporting improvements in diarrhea, abdominal pain, and gas/bloating.14 A later study, which used the S. boulardii strain CNCM I-745, administered the probiotic alone and also saw impressive elimination rates, with 80% of the probiotic group testing negative for SIBO after three months, as compared with 23.1% of the placebo group.15
While little to no research has directly examined Limosilactobacillus reuteri as a SIBO treatment per se, it has been studied for its potential to alleviate constipation and methane emissions. In a 2017 retrospective study, four weeks’ administration of a strain called DSM 17938 led to a “significant decrease of mean [methane] production,” with a “total disappearance” of methane in 55% of participants, as well as increased bowel movement frequency.16 It may, therefore, address both a prominent symptom of methane SIBO as well as an underlying cause of SIBO in general.
A spore-forming Bacillus species is one that produces resilient protective structures called endospores to survive harsh conditions. An example of such a species is B. coagulans, which was administered as the intervention in a 2019 IBS study. Using strain Unique IS2, the researchers reported B. coagulans led to “significant improvement” in symptoms such as abdominal discomfort/pain and bowel movement infrequency17 — a symptom and an underlying cause of SIBO.
Probiotics have a good short-term safety record, broadly speaking. For many people, side effects are limited to temporary gastrointestinal upset — abdominal cramping, nausea, flatulence, soft stools, and the like.18
But because we’re talking about SIBO probiotics, specifically, a minor side effect can compound existing symptoms. Consider, for example, that both SIBO- and probiotic-associated flatulence is a byproduct of bacterial fermentation, so here we have a case of the remedy potentially exacerbating a hallmark symptom, at least for a time. The resulting discomfort may be enough to qualify as a safety concern.
There’s also a rare but serious risk associated with probiotics that contain S. boulardii, which has been linked to a life-threatening infection called Saccharomyces fungemia. In a 2021 report, which examined 43 fungemia cases in Finland between 2009 and 2018, the United States Centers for Disease Control and Prevention reported that “at least 20” of the affected individuals were using S. boulardii probiotics, suggesting a correlation.19 The risk seems to apply largely to the immunocompromised, the critically ill, and people with indwelling catheters, but it’s something that all S. boulardii users should be aware of.
Of final note, be aware that, outside of S. boulardii, immunocompromise or critical illness may contraindicate you for probiotic supplementation in general, as even beneficial bacteria may become opportunistic pathogens under certain conditions.20 It’s risks like these that underscore the importance of consulting a doctor before adding a supplement to your health routine.
SIBO probiotics are principally for people with SIBO. To narrow it down, we’d say they’re best indicated for SIBO patients who:
These parameters leave us with a large exclusion cohort. Whereas with most other probiotics it’s more or less sensible to just try things out toward a nebulous objective such as “improving gut health,” SIBO probiotics are formulated with too narrow a set of outcomes to accommodate such a laissez-faire attitude. At best, a therapeutic failure would leave the user in the same poor condition as before; at worst, it could leave them with a life-threatening infection (rare) or at least temporarily worsen symptoms (not uncommon).
To prevent disappointment, approach SIBO probiotics with tempered expectations. Remember, SIBO is complex, and something as simple as over-the-counter supplementation may not present a true solution. Your due diligence should therefore include asking your doctor whether one of the probiotics in this guide is a reasonable treatment option for you specifically.
Best single-strain probiotic

Photo by Innerbody Research
Florastor Dual Action Probiotic rests on the strength of one strain that has performed well in research settings: S. boulardii CNCM I-745. In a 2024 randomized, placebo-controlled trial, for instance, it was this strain that led to an 80% SIBO elimination rate in the intervention group, compared with just 23.1% with placebo.15 Some earlier research yielded promising results, too, such as a 2023 pilot study in which the CNCM I-745 group exhibited greater decreases in hydrogen excretion and better improvements in IBS symptoms. The researchers concluded that CNCM I-745, especially when combined with a sensible diet, “reduced bacterial overgrowth and improved digestive symptoms while restoring the intestinal microbiota.”21 Also, keep in mind that S. boulardii is a yeast probiotic species, so it may accompany antibiotic therapy.
The results are encouraging, but should be interpreted with a sober eye. The studies were small, with only 33–54 participants apiece, and in the case of the 2024 trial the participants all had advanced liver disease. So, something like an 80% elimination rate can’t be reasonably extrapolated to the general SIBO public.
Still, CNCM I-745 is currently one of the best-studied probiotic solutions for SIBO, boasting direct supportive clinical research, and Florastor is a reputable brand whose CNCM I-745 has been administered to good effect in clinical gut health studies.22 Together these factors are why we’ve named Florastor Dual Action Probiotic our best single-strain option for SIBO.
Florastor does leave us with a lingering question as to dose, however, as it measures CNCM I-745 quantity in milligrams rather than the standard CFU. Florastor’s reasoning is that S. boulardii is a yeast probiotic, the average size of which is “approximately ten times the size of a single probiotic bacterial cell.” But we can make an educated guess as to Dual Action’s probiotic count based on a 2021 study, which equated 250mg of Florastor to 5 billion CFU.23 That would mean that a two-capsule, 500mg serving of Florastor Dual Action Probiotic contains 10 billion CFU, which is broadly congruent with research on CNCM I-745’s benefits for gut complaints such as diarrhea.24
Through the Florastor website, the Dual Action Probiotic is sold in four quantities:
| Servings | Price tag | Per-serving cost | |
|---|---|---|---|
| 20ct | 10 | $19.82 | $1.98 |
| 30ct | 15 | $28.97 | $1.93 |
| 50ct | 25 | $39.99 | $1.60 |
| 100ct | 50 | $67.99 | $1.36 |
At these price points, Florastor is significantly less cost-effective than our other recommendations, which range as low as $21.99 per bottle or $0.33 per serving.
Yet Florastor is the only brand in this guide that offers free shipping on nonsubscription items at a sub-$100 threshold. In fact, Florastor’s free-shipping threshold is just $24.99, which is a low barrier to cross, and anything above the 20ct option gets you there.
The return window is 30 days. Florastor’s policy isn’t well-delineated, but it leaves the possibility that opened items are eligible for a refund, contingent on approval.
Best multi-strain probiotic

Photo by Innerbody Research
Microbiome Labs RestorFlora combines four probiotic species, each specified down to the strain level and evidentially capable of improving SIBO symptoms:
S. boulardii CNCM I-1079 is different from Florastor’s I-745: it hasn’t been subject to direct SIBO studies, but it has performed well in tangential research. In a 2022 cellular study, for example, I-1079 appeared to protect intestinal cells from the inflammatory effects of Clostridioides difficile, a pathogenic species, which may loosely suggest therapeutic potential for SIBO-associated inflammation.24 Moreover, the results of a 2021 in vitro study suggest that CNCM I-1079 might help the gut microbiome recover from antibiotic disruption, which would bode well for patients taking it as an adjunct to antibiotics.25
B. subtilis HU58 has some of the clearest strain-specific human evidence for gastrointestinal symptoms associated with SIBO, namely diarrhea, abdominal pain, and stool consistency.
In a 2025 randomized clinical trial in children with antibiotic-associated diarrhea, 93.5% of the HU58 group returned to a normal stool consistency by the third day of treatment, and this group exhibited “significantly greater decreases in abdominal pain” compared with placebo.26 A 2026 study reported similar outcomes among adults with diarrhea-predominant IBS.27
Also known as Heyndrickxia faecalis SC208, this spore-forming strain was coadministered with B. subtilis HU58 in the aforementioned 2026 study in adults with diarrhea-predominant IBS.27 It was also administered both alone and together with HU58 in an open-label, placebo-controlled trial in 2020, where both the stand-alone and the combination treatment improved stool consistency, abdominal pain, bloating, and flatulence.28
B. clausii SC109 has the weakest evidence to support its place in the formulation, so its role is probably more complementary than anything else. The best supporting research we can point to is a 2021 laboratory experiment in which it, along with four other strains (including B. subtilis HU58 and B. coagulans SC208), increased propionate production in a colon model.29 Because propionate is an important short-chain fatty acid for overall gut health, SC109’s presence here may support the maintenance of a healthy colonic environment after SIBO elimination.
The sum of it is that the probiotics in Microbiome Labs may not have the same direct SIBO research support as Florastor, but its strains have mostly performed well against gastrointestinal symptoms that are characteristic of the condition.
Direct purchases through Microbiome Labs is a pain. First, you have to register an account. Then you have to get a medical practitioner’s approval to buy a product — odd, considering that RestorFlora is not a prescription medication.
To avoid all that, we recommend buying through a third party, such as Amazon, where a one-time purchase is $45.77 and a subscription costs $41.19. The one-timer is equal to the price point listed on the Microbiome Labs website, and the subscription cost is roughly $2.00 lower.
A single bottle contains 60 servings, or two months’ worth, so the per-serving cost equals no more than $0.76, which isn’t bad.
With Amazon, though, you probably can’t get a refund on an opened order, as the e-commerce conglomerate typically doesn’t allow returns of supplements. Microbiome Labs does have a return policy, with a 45-day window, but it involves a phone call to the company and explicit authorization of a return — similar to BioGaia. Only NOW’s direct return policy is worse, as it doesn’t allow returns on opened items at all.
Best for methane SIBO

Photo by Innerbody Research
BioGaia Gastrus Probiotic Chewables comprises two Limosilactobacillus reuteri strains with decent, albeit limited, supportive research behind them:
With regard to methane SIBO, DSM 17938 is the big one. In a 2017 retrospective study in 20 adults with functional constipation, this strain was found to decrease average methane production from 20.8ppm to 8.9ppm, with more than half of all participants seeing reductions to below 5ppm.16 That is, it successfully brought methane levels below the 10ppm threshold that’s diagnostic of methane overgrowth.30
ATCC PTA 6475 has mostly been studied for other outcomes, but ones that are related to SIBO. Most notably, in a 2024 randomized clinical trial in people with IBS-D, the strain appeared to improve gastrointestinal symptoms when administered alongside DSM 17938.31
The BioGaia chewables are pretty tasty, by the way. Somehow they remind us of Fruity Pebbles on the front end, and Smarties on the back. A palatable flavor isn’t something one normally expects from a probiotic, so we were pleasantly surprised.
BioGaia Gastrus Probiotic Chewables sell at multiple price points, one of which is a two-pack bulk:
| Servings | Price tag | Per-serving cost | |
|---|---|---|---|
| 1 bottle, one-time purchase | 30 | $28.99 | $0.97 |
| 1 bottle, subscription | 30 | $24.64 | $0.82 |
| 2 bottles, one-time purchase | 60 | $42.00 | $0.70 |
Buying one bottle as a one-time purchase isn’t as bad as Florastor, but it’s significantly costlier than Microbiome and NOW. The one-bottle subscription option is better, but also not as cost-effective as Microbiome or NOW. Only at the bulk level does the per-serving cost dip below that of Microbiome.
Subscriptions ship free, but all other orders get $6.95 tacked on to the bill.
The return policy is almost identical to that of Microbiome’s, except with a shorter, 30-day window. That is, you have 30 days to call (not email, but call) BioGaia to request approval on a return/refund.
Lowest up-front cost

Photo by Innerbody Research
NOW Foods Saccharomyces Boulardii contains 10 billion CFU of the eponymous probiotic yeast species, a clinically supported quantity.24 It doesn’t identify the strain of S. boulardii it uses — an obvious weakness, as probiotic benefits are strain-specific — but it can still do some good, seeing as S. boulardii in general has yielded gut health improvements in clinical research. Indeed, a 2015 systematic review notes that the S. boulardii family has reduced the risk of antibiotic-associated diarrhea in adults from 20.9% to 8.8%, a significant change.32 So, while we wish NOW Foods had used CNCM I-745 like Florastor, or even CNCM I-1079 like Microbiome Labs, its formulation as it stands still may be capable of improving SIBO symptoms.
Plus, with any NOW Foods supplement, you get a strong pedigree of official assurances. The Saccharomyces Boulardii supplement, in particular, boasts six certifications —
— so you can be confident you’re getting a product that is suitable for your dietary restrictions and that has been made under strict manufacturing practices.
You do, however, need to refrigerate the bottle after opening, which no other product in this guide requires.
NOW Foods Saccharomyces Boulardii is the most affordable SIBO probiotic among our recommendations. It’s sold in two quantities:
The 60ct bottle costs $0.73 per serving, which is $0.03 lower than that of Microbiome Labs and $0.03 higher than that of BioGaia at the bulk level. But with the 120ct bottle, the per-serving cost drops to $0.67, which handily beats any of our other recommendations.
No direct subscriptions, though, and no refunds on opened items. So the value benefit relates only to the up-front and per-serving costs, not to additional savings or purchase protection.
The best alternatives to SIBO probiotics — rather, what should be your first-line interventions — are prescription antibiotics and temporary dietary changes.
Antibiotics are the most established treatment approach. We reiterate that the American Gastroenterological Association advises that SIBO management ought to prioritize antibiotics alongside the correction of underlying causes.12 Although recurrence may still be possible, this approach presents the best odds of eliminating SIBO. If you’re using probiotics, they ought to play an adjunctive role.
As for dietary changes, you’ll want to follow what’s called an elemental diet, which replaces ordinary food with nutritionally complete substitutes whose nutrients are readily absorbed by the body, limiting the quantity of residues that small intestinal microbes can feed on. In a 2025 trial, this diet led to normalized breath tests in 73% of subjects with SIBO, as well as adequate symptom relief in 83%.33
These interventions are clinician-led. You might try a self-directed low-FODMAP diet instead, but the prognosis likely wouldn’t be as good compared with an elemental diet, prescription antibiotics, and possibly adjunctive probiotics.
Sources
Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Donaldson, G. P., Lee, S. M., & Mazmanian, S. K. (2015). Gut biogeography of the bacterial microbiota. Nature Reviews. Microbiology, 14(1), 20-32.
National Institute of Diabetes and Digestive and Kidney Diseases. (2017). Your digestive system & how it works. NIDDK.
American Gastroenterological Association. (2026). Small intestinal bacterial overgrowth (SIBO): Managing with diet. AGA.
Merck Manual. (2025). Small intestinal bacterial overgrowth (SIBO). Merck Manual.
Mayo Clinic Staff. (2024). Small intestinal bacterial overgrowth (SIBO): Symptoms and causes. Mayo Clinic.
Cleveland Clinic. (2024). SIBO (Small intestinal bacterial overgrowth). Cleveland Clinic.
Naylor, G., & Axon, A. (2003). Role of bacterial overgrowth in the stomach as an additional risk factor for gastritis. Canadian Journal of Gastroenterology, 17(Suppl. B), 13B-17B.
Nightingale, J. M. D., et al. (2020). The management of adult patients with severe chronic small intestinal dysmotility. Gut, 69(12), 2074-2092.
University of California Agriculture and Natural Resources. (2021). Ladybugs are good for your garden. UC ANR.
Zhong, C., et al. (2017). Probiotics for preventing and treating small intestinal bacterial overgrowth: A meta-analysis and systematic review of current evidence. Journal of Clinical Gastroenterology, 51(4), 300-311.
Niño, S. F., Santiesteban, M., & Muñoz Valencia, G., (2024). Efficacy of probiotic in the treatment of small intestinal bacterial overgrowth: Systematic review and meta-analysis. Revista de Gastroenterología del Perú, 44(3), 245-251.
Quigley, E. M. M., Murray, J. A., & Pimentel, M. (2020). AGA clinical practice update on small intestinal bacterial overgrowth: Expert review. Gastroenterology, 159(4), 1526-1532.
Harvard Medical School. (2025). Should you take probiotics with antibiotics? Harvard Health Publishing.
García-Collinot, G., et al. (2020). Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Digestive Diseases and Sciences, 65(4), 1134-1143.
Efremova, I., et al. (2024). Efficacy and safety of a probiotic containing Saccharomyces boulardii CNCM I-745 in the treatment of small intestinal bacterial overgrowth in decompensated cirrhosis: Randomized, placebo-controlled study. Journal of Clinical Medicine, 13(3), 919.
Ojetti, V., et al. (2017). Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: A retrospective study. European Review for Medical and Pharmacological Sciences, 21(7), 1702-1708.
Madempudi, R. S., et al. (2019). Randomized clinical trial: The effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Scientific Reports, 9, 12210.
Doron, S., & Snydman, D. R. (2015). Risk and safety of probiotics. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 60(Suppl 2), S129-S134.
Rannikko, J., et al. (2021). Fungemia and other fungal infections associated with use of Saccharomyces boulardii probiotic supplements. Emerging Infection Diseases, 27(8), 2043-2051.
Xu, R., Yu, Y., & Chen, T. (2025). Exploring the dark side of probiotics to pursue light: Intrinsic and extrinsic risks to be opportunistic pathogens. Current Research in Food Science, 10, 101044.
Fernández, L. M. B., Man, F., & Lasa, J. S. (2023). Impact of Saccharomyces boulardii CNCM I-745 on bacterial overgrowth and composition of intestinal microbiota in diarrhea-predominant irritable bowel syndrome patients: Results of a randomized pilot study. Digestive Diseases, 41(5), 798-809.
Kabbani, T. A., et al. (2016). Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes, 8(1), 17-32.
Wombwell, E., et al. (2021). The effect of Saccharomyces boulardii primary prevention on risk of hospital-onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with C. difficile infection. Clinical Infectious Diseases, 73(9), e2512-e2518.
Gaisawat, M. B., et al. (2022). Probiotics exhibit strain-specific protective effects in T84 cells challenged with Clostridioides difficile–infected fecal water. Frontiers in Microbiology, 12, 698638.
Duysburgh, C., et al. (2021). Lacticaseibacillus rhamnosus GG and Saccharomyces cerevisiae boulardii supplementation exert protective effects on human gut microbiome following antibiotic administration in vitro. Beneficial Microbes, 12(4), 59-73.
Sorensen, K., et al. (2025). Effects of spore-forming probiotic Bacillus subtilis HU58 in children with antibiotic-associated diarrhoea: A randomised, double-blind, placebo-controlled trial. Beneficial Microbes, 17(1), 1-10.
Sorensen, K., et al. (2026). Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal health: Results of a randomised, double-blind, placebo-controlled pilot study. Beneficial Microbes, 17(5), 491-502.
Mehta, D. S., et al. (2020). An open-labeled, placebo-controlled trial to evaluate the role of probiotics Bacillus subtilis HU58 and Bacillus coagulans SC208 on antibiotic-associated diarrhoea in humans. Biomedical Journal of Scientific & Technical Research, 22679-22684.
Marzorati, M., et al. (2021). Treatment with a spore-based probiotic containing five strains of Bacillus induced changes in the metabolic activity and community composition of the gut microbiota in a SHIME® model of the human gastrointestinal system. Food Research International, 149, 110676.
Pimentel, M., et al. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. American Journal of Gastroenterology, 115(2), 165-178.
König, J., et al. (2024). The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D — an exploratory RCT. PLOS ONE, 19(11), e0312464.
Szajewska, H., & Kołodziej, M. (2015). Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutics, 42(7), 793-801.
Rezaie, A., et al. (2025). Effect, Tolerability, and Safety of Exclusive Palatable Elemental Diet in Patients With Intestinal Microbial Overgrowth. Clinical Gastroenterology and Hepatology, 23(12), 2306-2317.
Cleveland Clinic. (2025). Have SIBO? Here’s the best and worst foods to eat. Cleveland Clinic.
Cruchet, S., et al. (2024). Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: A randomized controlled trial. Frontiers in Gastroenterology, 2, 1296048.
Tansel, A., & Levinthal, D. J. (2023). Understanding our tests: Hydrogen-methane breath testing to diagnose small intestinal bacterial overgrowth. Clinical and Translational Gastroenterology, 14(4), e00567.
Mechlińska, A., et al. (2025). Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies. Contemporary Oncology, 29(1), 11-21.